JNJ Submits Type II Variation Application To EMA For TECVAYLI As Monotherapy In RR Multiple Myeloma

Johnson & Johnson submitted a Type II variation application to the European Medicines Agency to seek approval for an indication extension of TECVAYLI (Teclistamab) as monotherapy. The article is truncated and does not specify the full patient population or additional details of the proposed extension.

Analysis

Johnson & Johnson submitted a Type II variation application to the European Medicines Agency to seek approval for an indication extension of TECVAYLI (Teclistamab) as monotherapy. The article is truncated and does not specify the full patient population or additional details of the proposed extension.